Therapy Areas: Oncology
BioArctic and Mesenkia sign research collaboration for glioblastoma antibody project
19 August 2026 - Swedish biopharma company BioArctic AB (STO: BIOA-B), which develops treatments for neurodegenerative diseases, said on Wednesday it has entered a research collaboration with Mesenkia...
Tolerance Bio licenses clinical-stage IL-7 therapy from NeoImmuneTech
19 August 2026 - Tolerance Bio Inc, a biotechnology company focused on preserving, regenerating and modulating thymic function to address immune diseases and extend healthspan, announced on Wednesday ...
Merck and Moderna report positive Phase 3 melanoma trial results
19 August 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, and biotechnology company Moderna Inc (NASDAQ:MRNA) announced on Wednesday that the Ph...
Scancell announces UK authorisation for Phase 3 melanoma trial
19 August 2026 - Immuno-oncology company Scancell Holdings plc (AIM: SCLP) announced on Wednesday that it has received Clinical Trial Authorization from the UK Medicines and Healthcare Products Regula...
Harbour BioMed IND for HBM7004 approved by China's NMPA
18 August 2026 - Global biopharmaceutical company Harbour BioMed (HKEX: 02142), which develops antibody therapeutics in immunology and oncology, said on Tuesday that China's National Medical Prod...
Can-Fite reports preclinical data supporting Phase IIb pancreatic cancer study
17 August 2026 - Israel-based clinical-stage biotechnology company Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF), which develops small-molecule drugs for oncological and inflammatory disea...